Interested in knowing more about the conference? Check out our conference program to know more about our speakers and panels.
Timothy Lu, Ph.D.
Timothy Lu is an Associate Professor leading the Synthetic Biology Group in the Department of Electrical Engineering and Computer Science and the Department of Biological Engineering at MIT. Tim graduated with his SB and MEng from MIT, and his MD/PhD from the Harvard-MIT Health Sciences and Technology program. He is a core member of the MIT Synthetic Biology Center and a co-founder of multiple biotechnology companies innovating new diagnostic and therapeutic technologies for human health, including Sample6, Senti Biosciences, Synlogic, Eligo Biosciences, BiomX, and Engine Biosciences.
Tim’s research at MIT focuses on engineering platforms for computing and memory in living cells and applying these to create adaptive medicines as next-generation cell and gene therapies for important human diseases. His work also includes developing novel technology platforms to interrogate and correct diseased cell states. He is a recipient of the ACS Synthetic Biology Young Investigator Award, the Biochemical Engineering Journal Young Investigator Award, the NIH New Innovator Award, the Presidential Early Career Award for Scientists and Engineers, and the Ellison Medical Foundation New Scholar in Aging Award, among others.
Humayun Irshad, Ph.D.
A computer scientist with expertise’s in machine learning, deep learning, computer vision, medical image analysis and statistical methods. He is developing computational techniques to combine computer vision, machine learning and statistical approaches for automated object detection, segmentation and classification in 2D and 3D images and application ranging from medical, retail, self-driving car, satalite, drones, etc. He has completed a 3 years PostDoc at Harvard Medical School and also received a PhD in Computer Science from University of Grenoble France, where he developed machine learning and deep learning techniques include region of interest detection and classification, and nuclei and gland detection, segmentation and classification in 2D and 3D histopathological images (H&E stained, IHC stained and fluorescence images).
Chun-Hao Huang, Ph.D.
Chun-Hao is a cancer biologist, genetic engineer and AI entrepreneur. He received his postdoctoral training under the mentorship of HHMI investigator Professor Jennifer Doudna at UC Berkeley, and Ph.D. in HHMI investigator Professor Scott Lowe’s Lab at Memorial Sloan-Kettering Cancer Center & Weill Cornell Medicine. He pioneered the establishment of fast and flexible genetically engineered preclinical mouse models using gene silencing and editing technologies, and led the discovery of therapeutic strategies for treating liver cancer and inflammatory bowel disease. He also invented methods to identify disease biomarkers, and applied machine learning to the study of genes.
Chun-Hao is UN’s Sustainable Development Goals Talent and Winner of the UNLEASH Innovation Lab, Fellow of the 64th Lindau Nobel Laureate Meeting, 2018 MIT Technology Review Innovator Under 35 Asia Pacific, and co-organizer of the 2018 SingularityU APAC Global Impact Challenge. He received a Google and Genentech Scholarship to attend Singularity University in NASA Ames to co-found Clinicai, a startup that brings bio and space technologies to our daily life for continuously health monitoring and non-invasive early cancer detection.
Cheng-Chiu Huang, Ph.D.
Coming to the US from Yilan, Taiwan, Cheng-Chiu received his Ph.D. in Developmental Biology at Baylor College of Medicine. He then had postdoctoral training in Neurobiology, Anesthesiology, and Dermatology at Howard Hughes Medical Institute - Janelia Research Campus and Washington University in St. Louis.
Cheng-Chiu is with an early discovery team at Merck working on sensory, autonomic, and muscle physiology. He managed a pipeline project on postsurgical analgesia at TLC Biopharmaceuticals toward successful IND application. He has also led several academic programs on peripheral sensory neuropathy, ocular and skin allergy, and neural circuitry formation, using a wide variety of molecular, genetic, and pharmacological approaches.
Peter L. Lu, M.D.
Dr. Lu founded Arbor Vita Corporation in 1998 to develop novel therapeutics and diagnostics in oncology for clinical use.
Prior to Arbor Vita, he was on the faculty at Stanford University School of Medicine and directed the Psoriasis Treatment Center. He founded the Papua New Guinea Medical Project, the longest running international medicine program at Stanford.
Dr. Lu received a M.S. (Micro/Immuno) and M.D. (with honors) from the University of Washington and a B.S. in biology from the California Institute of Technology (Caltech). He completed his residency in Dermatology at Stanford University School of Medicine and fellowship with Dr. Mark Davis at Howard Hughes Medical
Asia Chang is the Commercial Strategy and Operations Leader at Freenome. Freenome is an AI-genomics company decoding cell-free biomarker patterns from cancer screening
blood tests. Breakthroughs in artificial intelligence (AI) turn hidden patterns into signatures for early detection of cancer. Asia Chang previously led the Oncology Product Management
and Biopharma Partnering teams at Thermo Fisher Scientific’s Clinical Next-Generation Sequencing division. The Oncomine NGS solutions developed by his team targeted solid
tumors, hematologic malignancies, liquid biopsies, and immuno-oncology tests. Previously, Mr. Chang led strategic consulting engagements for biopharma and diagnostics companies with L.E.K. Consulting in the U.S. and in China. He also developed minimally invasive implantable medical devices as an R&D bioengineer with Johnson & Johnson. He has a BS in Materials Science and Engineering from UC, Berkeley and a Masters in Bioscience from the Keck Graduate Institute.
Mr. Chih-cheng Yeh received his first MS degree in
Mechanical Engineering, National Central University,
Taiwan, in 1990. He started his career as an Associate
Engineer at the Metal Industrial Research and Development
Center(MIRDC) (1992-1993); then, served for National
Science Council as a program manager (1996-2001). In
1999, he won a full scholarship from British Council, UK,
then received his second MS degree in Space Engineering,
Cranfield University, UK in 2000. From 2001 to 2004, he
was the Science & Technology Officer for Science and
Technology Division, Taipei Economic and Cultural Office
in San Francisco. With three years overseas experience,
he was recruited to the Ministry of Economic Affairs as the
Minister Mei-Yueh Ho’s Special Assistant (2004-2006). In
2006-2010, Mr. Yeh was promoted to be the Section Chief,
Deputy Director of Industrial Development Bureau(IDB),
Ministry of Economic Affairs. During this period, he had
been responsible for aeronautics, vehicle, and shipbuilding
industries’ development. He also attended the negotiation
of Early Harvest List, Economic Cooperation Framework
Agreement(ECFA), with China. With 6 years industrial
development experience, he returned to the National Science
Council as Deputy Director General, then Director General to
in charge of Science and Technology Planning (2010-2016).
With his industrial development and R/D management
experience, he has been appointed to take the position as
the Director to the Science and Technology Division, Taipei
Economic and Cultural Office in San Francisco, also know
as the liaison office for Ministry of Science and Technology,
Taiwan, in San Francisco.
Sandra Lee is a manager in a hospital system with one
main medical center and 11 clinics. She is experienced
in hospital administration, clinic operation, data analysis,
strategy planning and medical supply chain. She provides
ongoing performance evaluations to support hospital
operation needs and to meet changing regulatory agencies
standards. She maintains budgeting and staffing portfolio
for over 1,400 staffs. She is also a liaison between clinics,
county, state and federal agencies.
Prior to her current role, Sandra was a Senior Clinical
Quality Research Analyst at Adventist Health corporate
office, which owns 20 acute care hospitals across four
states in the U.S. She provided analytical and clinical quality
improvement decision supports to various departments.
Sandra is a licensed and registered pharmacist in Taiwan.
She practiced in Taipei Veterans General Hospital and a
retail pharmacy as a front line pharmacist. She has solid
backgrounds and professional skills in pharmacy, hospital
management, operation performance evaluations, clinical
quality initiative implementation and medical equipment
control. Sandra has a M.S. in Clinical Pharmacy from
National Cheng Kung University, a M.P.H from Loma Linda
University, and a B.S. in Pharmacy from Taipei Medical
University. She is certified in Public Health in U.S.